Chromatin-modifying enzymes as modulators of reprogramming by Onder, Tamer T. et al.
LETTER
doi:10.1038/nature10953
Chromatin-modifying enzymes as modulators of
reprogramming
Tamer T. Onder1,2,3,4, Nergis Kara5, Anne Cherry1,2,3,4, Amit U. Sinha6,7, Nan Zhu3,6,7, Kathrin M. Bernt3,6,7, Patrick Cahan1,2,3,4,
B. Ogan Mancarci8, Juli Unternaehrer1,2,3,4, Piyush B. Gupta9,10, Eric S. Lander9,11,12, Scott A. Armstrong3,6,7
& George Q. Daley1,2,3,4,6,13,14
Generation of induced pluripotent stem cells (iPSCs) by somatic
cell reprogramming involves global epigenetic remodelling1.
Whereas several proteins are known to regulate chromatin marks
associated with the distinct epigenetic states of cells before and
after reprogramming2,3, the role of specific chromatin-modifying
enzymes in reprogramming remains to be determined. To address
how chromatin-modifying proteins influence reprogramming, we
used short hairpin RNAs (shRNAs) to target genes in DNA and
histonemethylation pathways, and identified positive and negative
modulators of iPSC generation. Whereas inhibition of the core
components of the polycomb repressive complex 1 and 2, including
the histone 3 lysine 27 methyltransferase EZH2, reduced repro-
gramming efficiency, suppression of SUV39H1, YY1 and DOT1L
enhanced reprogramming. Specifically, inhibition of the H3K79
histone methyltransferase DOT1L by shRNA or a small molecule
accelerated reprogramming, significantly increased the yield of
iPSC colonies, and substituted for KLF4 and c-Myc (also known
as MYC). Inhibition of DOT1L early in the reprogramming
process is associated with a marked increase in two alternative
factors, NANOG and LIN28, which play essential functional roles
in the enhancement of reprogramming. Genome-wide analysis of
H3K79me2 distribution revealed that fibroblast-specific genes
associated with the epithelial to mesenchymal transition lose
H3K79me2 in the initial phases of reprogramming. DOT1L inhibi-
tion facilitates the loss of this mark from genes that are fated to be
repressed in the pluripotent state. These findings implicate specific
chromatin-modifying enzymes as barriers to or facilitators of
reprogramming, and demonstrate how modulation of chromatin-
modifying enzymes can be exploited to more efficiently generate
iPSCs with fewer exogenous transcription factors.
To examine the influence of chromatin modifiers on somatic cell
reprogramming, we used a loss-of-function approach to interrogate
the role of 22 select genes in DNA and histone methylation pathways.
We tested a pool of three hairpins for each of 22 target genes and
observed knockdown efficiencies of .60% for 21 out of 22 targets
(Supplementary Fig. 1). We infected fibroblasts differentiated from
the H1 human embryonic stem cell (ESC) line (dH1fs) with shRNA
pools, transduced them with reprogramming vectors expressing
OCT4 (also known as POU5F1), SOX2, KLF4 and c-Myc (OSKM),
and identified the resulting iPSCs by Tra-1-60 staining (Fig. 1a)4. Eight
shRNA pools reduced reprogramming efficiency (Fig. 1b). Among the
target genes were OCT4 (included as a control), and EHMT1 and
SETDB1, two H3K9 methyltransferases whose histone mark is asso-
ciated with transcriptional repression. The remaining five shRNA
pools targeted components of polycomb repressive complexes
(PRC),majormediators of gene silencing and heterochromatin forma-
tion5. Inhibition of PRC1 (BMI1, RING1) and PRC2 components
(EZH2, EED, SUZ12) significantly decreased reprogramming effi-
ciency while having negligible effects on cell proliferation (Fig. 1c
and Supplementary Fig. 2). This finding is of particular significance
given that EZH2 is necessary for fusion-based reprogramming6 and
highlights the importance of transcriptional silencing of the somatic
cell gene expression program during generation of iPSCs.
In contrast to genes whose functions seem to be required for repro-
gramming, inhibition of three genes enhanced reprogramming: YY1,
SUV39H1 and DOT1L (Fig. 1b, d). YY1 is a context-dependent
transcriptional activator or repressor7, whereas SUV39H1 is a histone
H3K9 methyltransferase implicated in heterochromatin formation8.
Interestingly, enzymes that modify H3K9 were associated with both
inhibition and enhancement of reprogramming, which suggested that
unravelling the mechanisms for their effects might be challenging.
Thus, we focused onDOT1L, a histone H3 lysine 79methyltransferase
that has not previously been studied in the context of reprogramming9.
We used two hairpin vectors that resulted in the most significant
downregulation of DOT1L and concomitant decrease in global
H3K79 methylation levels (Supplementary Fig. 3a, b). Fibroblasts
expressing DOT1L shRNAs formed significantly more iPSC colonies
when tested separately or in a context where they were fluorescently
labelled and co-mixed with control cells (Fig. 2a and Supplementary
Fig. 4). This enhanced reprogramming phenotype could be reversed
by overexpressing an shRNA-resistant wild-type DOT1L, but not a
catalytically inactive DOT1L, indicating that inhibition of catalytic
activity of DOT1L is key to enhance reprogramming10 (Fig. 2a). Our
findings with dH1fs were applicable to other human fibroblasts, as
IMR-90 and MRC-5 cells also showed threefold and sixfold increases
in reprogramming efficiency, respectively, upon DOT1L suppression
(Supplementary Fig. 5). To validate our findings independently of
shRNA-mediated knockdown, we used a recently discovered small
molecule inhibitor of DOT1L catalytic activity. EPZ004777 (ref. 11,
referred to as iDot1L) abrogatedH3K79methylation at concentrations
ranging from 1mM to 10mM and increased reprogramming efficiency
three- to fourfold (Fig. 2b and Supplementary Fig. 6a, b). Combination
of inhibitor treatment with DOT1L knockdown did not further
increase reprogramming efficiency, reinforcing our previous
observation that inhibition of the catalytic activity of DOT1L is
key to reprogramming (Supplementary Fig. 6c). iPSCs generated
through DOT1L inhibition showed characteristic ESC morphology,
immunoreactivity for SSEA4, SSEA3, Tra-1-81, OCT4 and NANOG,
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and differentiated into all three embryonic germ layers in vitro
and in teratomas (Supplementary Fig. 7a–c). Therefore, iPSCs
generated following DOT1L inhibition display all of the hallmarks of
pluripotency.
We next assessed DOT1L inhibition in murine reprogramming.
iDot1L treatment led to threefold enhancement of reprogramming
of mouse embryonic fibroblasts carrying an OCT4-GFP (green
fluorescent protein) reporter gene (OCT4–GFP MEFs; Fig. 2c).
Reprogramming of tail-tip fibroblasts (TTFs) derived from a con-
ditional knockout DOT1L mouse strain yielded significantly more
iPSC colonies upon deletion of DOT1L12 (Supplementary Fig. 8a).
Cre-mediated excision of both floxed DOT1L alleles in iPSC clones
derived from homozygous TTFs was confirmed by genomic PCR
(Supplementary Fig. 8b). DOT1L inhibition also increased reprogram-
ming efficiency of MEFs and peripheral blood cells derived from an
inducible secondary iPSC mouse strain13 (Supplementary Fig. 8c, d).
Taken together, these results demonstrate that DOT1L inhibition
enhances reprogramming of both mouse and human cells.
We next examined the cellular mechanisms by which DOT1L
inhibition promotes reprogramming. DOT1L inhibition affected nei-
ther retroviral transgene expression nor cellular proliferation
(Supplementary Fig. 9a–c). Although previous studies indicated that
DOT1L-null cells have increased apoptosis and accumulation of cells
in G2 phase9, we failed to observe a significant increase in apoptosis or
change in the cell cycle profile of DOT1L-inhibited fibroblasts
(Supplementary Fig. 9d, e). In human iPSC clones derived from
shDot1L fibroblasts, DOT1L inhibition was no longer evident, reflect-
ing the known silencing of retroviruses that occurs during reprogram-
ming (Supplementary Fig. 10a). Quantitative PCR (qPCR) analysis
revealed that the silencing occurred by day 15 after OSKM transduc-
tion (Supplementary Fig. 10b, c). To define the crucial timewindow for
DOT1L inhibition, we treated fibroblasts with iDot1L at 1-week inter-
vals during reprogramming. iDot1L treatment in either the first or
second week was sufficient to enhance reprogramming, whereas treat-
ment in the third week or a 5-day pretreatment had no effect
(Supplementary Fig. 10d, e). Immunofluorescence analysis revealed
significantly greater numbers of Tra-1-60-positive cell clusters on
day 10 and day 14 in shDot1L cultures (Supplementary Fig. 11a, b),
indicating that the emergence of iPSCs is accelerated upon DOT1L
inhibition. When we extended the reprogramming experiments by 10
more days, shDot1L cells still yieldedmore iPSC colonies than controls
(Supplementary Fig. 11c). Taken together, these findings indicate that
DOT1L inhibition acts in early to middle stages to accelerate and
increase the efficiency of the reprogramming process.
To assess whether DOT1L inhibition could replace any of the repro-
gramming factors, we infected control and DOT1L-inhibited fibro-
blasts with three factors, omitting one factor at a time. In the absence of
OCT4 or SOX2 no iPSC colonies emerged (Fig. 2d).When we omitted
either KLF4 or c-Myc, DOT1L-inhibited fibroblasts gave rise to robust
numbers of Tra-1-60-positive colonies, whereas control cells gener-
ated very few colonies, as reported previously4 (Fig. 2d–f and Sup-
plementary Fig. 12a). Importantly, DOT1L-inhibited fibroblasts
transduced with only OCT4 and SOX2 gave rise to Tra-1-60-positive
colonies, whereas control fibroblasts did not (Fig. 2d–f). These two-
factor iPSCs showed typical ESCmorphology, silenced the reprogram-
ming vectors and had all of the hallmarks of pluripotency as gauged by
endogenous pluripotency factor expression and the ability to form all
three embryonic germ layers in vitro and in teratomas (Supplementary
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Figure 1 | Screening for inhibitors and enhancers of reprogramming.
a, Timeline of shRNA infection and iPSC generation. b, Number of Tra-1-601
colonies 21 days after OSKM transduction of 25,000 dH1f cells previously
infected with pools of shRNAs against the indicated genes. Representative Tra-
1-60-stained reprogramming wells are shown. The dotted lines indicates 3
standard deviations from the mean number of colonies in control wells.
c, Validation of primary screen hits that decrease reprogramming efficiency.
Fold change in Tra-1-601 iPSC colonies relative to control cells. *P, 0.05,
**P, 0.01 compared to control shRNA-expressing fibroblasts (n5 4; error
bars, 6s.e.m.). Representative Tra-1-60-stained wells are shown. d, Validation
of primary screen hits that increase reprogramming efficiency. Fold change in
Tra-1-601 iPSC colonies relative to control cells. *P, 0.05, **P, 0.01
compared to control shRNA-expressing fibroblasts (n5 4; error
bars,6 s.e.m.). Representative Tra-1-60-stained wells are shown.
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Figs 7a–c and 12b). PCR on genomic DNA isolated from expanded
colonies confirmed the absence of integrated KLF4 and c-Myc trans-
genes (Supplementary Fig. 12c). Thus, we were able to generate two-
factor iPSCs either by suppression of DOT1L expression or chemical
inhibition of its methyltransferase activity.
To gain insights into the molecular mechanisms of how DOT1L
inhibition promotes reprogramming and replaces KLF4we performed
global gene-expression analyses on control and shDot1L fibroblasts
before and 6 days after OSKM andOSM transduction, along with cells
that were treated with iDot1L. Relatively few genes were differentially
expressed in shDot1L cells on day 6 of reprogramming (22 up, 23
down; Supplementary Table 3). Inhibitor-treated cells showed broader
gene expressionchanges (405upand175down; SupplementaryTable 3),
presumably due to more complete inhibition of K79me2 levels (Fig. 3a).
In the absence of KLF4, 94 genes were differentially upregulated in
shDot1L cells; intersection of this set of genes with the set differentially
upregulated in four-factor reprogramming of DOT1L-inhibited cells
yielded only five common genes (Fig. 3a, b). We were particularly
intrigued to find NANOG and LIN28 upregulated in all three instances
of DOT1L inhibition, because these two genes are part of the core
pluripotency network of human ESCs14,15 and can reprogram human
fibroblasts into iPSCswhen used in combinationwithOCT4 and SOX2
(ref. 16).
We explored the possibility that NANOG and LIN28 upregula-
tionmight account for the enhanced reprogramming observed follow-
ing DOT1L inhibition, and validated their upregulation in shDot1L
fibroblasts uponOSMorOS transduction (Supplementary Fig. 13a, b).
Interestingly, at this early time point REX1 (also known as ZFP42) and
DNMT3B, two other well-characterized pluripotency genes, were not
upregulated, indicating that DOT1L inhibition does not broadly
upregulate the pluripotency network. Suppression of either Nanog
or Lin28 abrogated the two-factor (OS) reprogramming of shDot1L
fibroblasts, indicating the essential roles of NANOG and LIN28 in this
process (Fig. 3c and Supplementary Fig. 13c). DOT1L inhibition also
led to increased NANOG expression in the context of OCT4, SOX2
and LIN28 (OSL) and LIN28 expression in the context ofOCT4, SOX2
and NANOG (OSN) (Supplementary Fig. 14a). Furthermore, DOT1L
inhibition significantly increased the efficiency of three-factor repro-
gramming in the context of OSN and OSL (Supplementary Fig. 14b).
Finally, inclusion ofNANOGand LIN28 in theOSKMreprogramming
cocktail did not confer any additional enhancement to shDot1L cells
(Fig. 4d and Supplementary Fig. 14c). Taken together, these data
implicate NANOG and LIN28 in the enhancement of reprogramming
and replacement of KLF4 and c-Myc with DOT1L inhibition.
To gain insight into the genome-wide chromatin changes that are
facilitated by DOT1L inhibition, we performed chromatin immuno-
precipitation followed byDNA sequencing (ChIP-seq) for H3K79me2
and H3K27me3 in human ESCs as well as fibroblasts undergoing
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Figure 2 | DOT1L inhibition enhances reprogramming efficiency and
substitutes for KLF4 andMyc. a, Fold change in the reprogramming efficiency
of dH1f cells infected with two independentDOT1L shRNAs or co-infected with
shRNA-1 and a vector expressing an shRNA-resistant wild-type or catalytically
dead mutant DOT1L. Data correspond to the average and s.e.m.;
n5 independent experiments. *P, 0.01 compared to control shRNA-
expressing fibroblasts. b, Fold change in the reprogramming efficiency of dH1f
cells treated with iDot1L at the indicated concentrations for 21days. Data
correspond to the mean6 s.d.; n5 3. *P, 0.001 compared to untreated
fibroblasts. c, Number of alkaline-phosphatase-positive (AP1) colonies derived
from OSKM-transduced untreated or iDot1L-treated (10mM) OCT4–GFP
MEFs. *P, 0.001 compared untreated MEFs (n5 4; error bars,6 s.d.).
Representative AP-stained wells are shown. d, Tra-1-60 stained of plates of
shCntrl and shDot1L fibroblasts in the absence of each factor or both KLF4 and
c-Myc. e, Tra-1-60-stained plates of untreated and iDot1L treated (3.3mM)
fibroblasts in the absenceof each factor or bothKLF4andc-Myc. f,Quantification
of the Tra-1-601 colonies in Fig. 2d, e representing mean and s.d. of two
independent experiments done in triplicate.
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Figure 3 | NANOG and LIN28 are required for enhancement of
reprogramming by DOT1L inhibition. a, Overlap of differentially
upregulated genes in shDot1L cells 6 days post-OSKM and OSM transduction
with the genes upregulated in OSKM-transduced iDot1L-treated cells. b, Heat
maps showing differential expression levels of commonly upregulated genes in
OSKM-transduced DOT1L-inhibited cells. c, Number of Tra-1-601 iPSC
colonies upon knockdown of Nanog or Lin28 in 2-factor reprogramming of
shDot1L cells. Data represent mean and s.e.m of 2 independent experiments
done in triplicate. d, Fold-change in Tra-1-601 iPSC colonies in 4-factor
(OSKM) and 6-factor (OSKMNL) reprogramming of shCntrl and shDot1L
fibroblasts. Data represent mean and s.e.m. of two independent experiments
done in duplicate. Representative Tra-1-60-stained wells are shown above.
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reprogramming, with or without iDot1L treatment (Supplementary
Fig. 15). In both ESCs and fibroblasts, H3K79me2 is positively asso-
ciated with transcriptionally active genes and negatively associated
with genes marked by H3K27me3 (Supplementary Fig. 16a–c). ESC-
specific genes marked by H3K79me2 included pluripotency factors, a
subset of their downstream targets, and genes involved in epithelial cell
adhesion such as CDH1 (E-cadherin) (280 genes; Supplementary
Fig. 17a, b and Supplementary Tables 4, 5). In contrast, in fibroblasts,
genes marked by H3K79me2 were significantly enriched in genes
induced during the epithelial to mesenchymal transition (EMT) (377
genes; Supplementary Fig. 17a).
Among the 348 genes that showed reduced H3K79me2 6 days after
OSKM expression, we likewise found a significant enrichment of gene
sets associated with the induction of a mesenchymal state, including
SNAI2, TGFB2 and TGFBR1 (Supplementary Fig. 18a)17,18. Only a few
of these genes showed decreased expression at day 6 (12 out of 348),
but the vast majority of them lacked this mark in the pluripotent state
(272 out of the 348 devoid of H3K79me2 in ESCs), suggesting they
were destined for transcriptional silencing during reprogramming.
This finding prompted us to ask whether DOT1L inhibition results
in the removal of H3K79me2 from such fibroblast-specific, EMT-
associated genes. UponDOT1L inhibitor treatment, H3K79me2 levels
were reduced on almost all loci, with the exception of a subset
comprised mostly of housekeeping genes that also had high levels of
H3K79me2 in ESCs (Supplementary Fig. 19a). Strikingly, the genes
that lost proportionally the most H3K79me2 in inhibitor-treated
fibroblasts during reprogramming (eightfold or more) were again
highly enriched in genes induced in EMT (Supplementary Fig. 19b).
Mesenchymal master regulators such as SNAI1, SNAI2, ZEB1, ZEB2
and TGFB2 were among these genes (Fig. 4a)19. In the presence of the
DOT1L inhibitor, these regulators were more strongly repressed
during reprogramming, whereas epithelial genes such as CDH1 and
OCLN were more robustly upregulated (Fig. 4b). The extinction of
fibroblast gene expression was accompanied by increased deposition
of the repressive H3K27me3 mark on the majority of fibroblast-
specific regulators examined (Supplementary Fig. 20). In contrast,
H3K27me3 was depleted to a greater extent on SOX2 and E-cadherin
promoters, reflecting their activation during reprogramming. Finally,
the H3K27me3 status of master regulators of other lineages, such as
OLIG2, MYOD1, NKX2-1 and GATA4, remained unchanged upon
DOT1L inhibitor treatment, indicating that the deposition of
H3K27me3 was specific to fibroblast-specific regulators.
To test the functional importance of downregulationofmesenchymal
regulators in the iDot1L-mediated enhancement of reprogramming,
we overexpressed TWIST1, SNAI1 and ZEB1 or added soluble TGF-
b2 to cells undergoing reprogramming in the presence of the DOT1L
inhibitor. All of these perturbations significantly counteracted the
enhancement observed with DOT1L inhibition (Fig. 4c). Interestingly,
expression of these factors also abrogated the iDot1L-mediated upregu-
lation of NANOG and LIN28, suggesting that the effect of DOT1L
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Figure 4 | Genome-wide analysis of H3K79me2 marks during
reprogramming. a, H3K79me2 ChIP-sequencing tracks (blue) for select
EMT-associated genes in fibroblasts (Fib) and ESCs along with the
corresponding H3K27me3 tracks in ESCs (red). b, Expression of EMT-
associated transcription factors (EMT-TF) and epithelial genes in control and
iDot1L-treated fibroblasts at the indicated time points during reprogramming.
qPCR was normalized to uninfected fibroblasts for EMT-TFs and H1 ESCs for
CDH1 and OCLN. c, Number of Tra-1-601 colonies derived from untreated
and iDot1L-treated (3.3mM) dH1f cells that are either infected with SNAI1,
TWIST1 or ZEB1 expression vectors or treated with soluble TGF-b2
(2 ngml21) (n5 3; error bars,6 s.d.). Representative Tra-1-60-stained wells
are shown. d, qRT–PCR quantification of NANOG mRNA level on day 6 of
OSKM-expressing untreated or iDot1L-treated (3.3mM) fibroblasts expressing
the indicated EMT-factors. Expression levels were normalized to those
observed in H1 ESCs. e, qRT–PCR quantification of LIN28A mRNA level on
day 6 of OSKM-expressing untreated or iDot1L-treated (3.3mM) fibroblasts
expressing the indicated EMT-factors. Expression levels were normalized to
those observed in H1 ESCs.
LETTER RESEARCH
2 9 M A R C H 2 0 1 2 | V O L 4 8 3 | N A T U R E | 6 0 1
Macmillan Publishers Limited. All rights reserved©2012
inhibition on these two pluripotency genes is likely to be indirect
(Fig. 4d, e). Conversely, we tested whether destabilization of the
mesenchymal state by inhibition of TGF-b signalling would be redund-
ant with DOT1L inhibition. A small molecule inhibitor of TGF-b
signalling (SB431542) increased reprogramming efficiency, but in com-
bination with the DOT1L inhibitor, showed no significant further
increase in iPSC colonies (Supplementary Fig. 21). Taken together these
data indicate that in fibroblasts, downregulation of the mesenchymal
gene expression program is critical to enhancement of reprogramming
by DOT1L inhibition.
Our loss-of-function survey indicates that chromatin-modifying
enzymes play critical roles for both reactivating silenced loci as well
as reinstating closed domains of heterochromatin during the global
epigenetic remodelling of differentiated cells to pluripotency, thus
implicating specific enzymes as facilitators or barriers to cell fate tran-
sitions. DOT1L inhibition seems to enhance reprogramming at least in
part by facilitating loss of H3K79me2 from fibroblast genes whose
silencing is required for reprogramming (Supplementary Fig. 22).
Interestingly, KLF4, which can be replaced by DOT1L inhibition,
has been shown to facilitate a mesenchymal to epithelial transition
(MET) by inducing E-cadherin expression20. Persistent H3K79me2
at the fibroblast master regulators during the initial phases of repro-
gramming seems to prevent shutdown of these genes, thus hindering
the acquisition of an epithelial phenotype concomitant with delayed
activation of NANOG and LIN28. In this regard H3K79me2 acts as a
barrier to efficient repression of the somatic program by the repro-
gramming factors. This notion is consistent with the role of Dot1 in
yeast, where it antagonizes gene repression21. As reprogramming of
blood cells is also enhanced by DOT1L inhibition, we speculate that
DOT1L inhibition may enhance reprogramming in a broad range of
cell types by facilitating the silencing of lineage-specific programs of
gene expression. Finally, our results also demonstrate that specific
chromatin modifiers can be modulated to generate iPSCs more effi-
ciently and with fewer exogenously introduced transcription factors.
METHODS SUMMARY
shRNAs were designed using the RNAi Codex22. 97-mer oligonucleotides (Sup-
plementary Table 1) were PCR-amplified and cloned into theMSCV-PM23 vector.
Reprogramming assays were carried out with either retroviral4 or lentiviral16
reprogramming vectors. dH1f cells were previously described4. For gene expres-
sion analyses, total RNA was extracted from two or three independent culture
plates for each condition and transcriptional profiling was performed using
Affymetrix U133Amicroarrays. ChIP-seq was performed as described with slight
modifications12.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
shRNA cloning. shRNAs were designed using the RNAi Codex22. 97-mer oligos
(Supplementary Table 1) were amplified with the following primer pair: Forward:
GATGGCTGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG, reverse:
GTCTAGAGGAATTCCGAGGCAGTAGGC. PCR products were gel-purified,
digested with EcoRI and XhoI and ligated into theMSCV-PM vector. Clones were
verified by sequencing. shRNA targeting the firefly luciferase was used as a con-
trol23. NANOG shRNA was previously described24.
Production of viral supernatants. 293T cells were plated at a density of 2.53 106
cells per 10-cm dish. The next day, cells were transfected with 2.5mg viral vector,
2.25mg Gag-Pol vector and 0.25mg VSV-G plasmid using 20ml Fugene 6 (Roche
Applied Science) in 400ml DMEM per plate. Supernatant was collected 48 h and
72h post-transfection and filtered through 45-mm pore size filters. For concen-
tration, viral supernatants were mixed with PEG3350 solution (Sigma P3640,
dissolved in PBS, 10% final concentration) and left overnight at 4 uC. The next
day, supernatants were centrifuged at 2,500 r.p.m. for 20min, and the pellets were
re-suspended in PBS. Titering was performed on 293Ts. For shRNA infections,
500ml of unconcentrated viral supernatant was used to infect 25,000 cells in the
presence of 10mgml21 protamine sulphate. For fluorescent labelling of dH1fs, we
used lentiviruses PRRL-GFP (Addgene catalogue no. 12252) and FUdGW-
Tomato (Addgene catalogue no. 22771).
Reprogramming assays. dH1f cells were first infected with shRNAviruses at high
multiplicity of infection (m.o.i.) to ensure all cells received at least one vector
(gauged by puromycin resistance of parallel infected wells). 25,000 shRNA-
infected dH1f cells were then plated per well in 12-well plates and infected over-
night with either retroviral (m.o.i. 2.5)25 or lentiviral (Addgene catalogue no.
21162, 21164; 100–200ml supernatant)26 reprogramming factors. For two-factor
reprogramming,OCT4 and SOX2 viruses were used at anm.o.i. of 5. Six days later,
cells were trypsinized and re-plated 1:4 or 1:6 onto six-well plates. Medium was
changed to hESmediumdaily until day 21 when plates were fixed. Small molecule
inhibitor of DOT1L, EPZ004777 (a gift from Epizyme, Inc.) was dissolved in
DMSO as a 10mM stock and was added at the indicated concentrations. For
DOT1L rescue experiments, an MSCV-based retroviral vector encoding human
DOT1L with or without mutations in the SAM-binding site (gifts of Y. Zhang)
were mutagenized at the shRNA target site using a QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies). In certain experiments,
NANOG and LIN28 expression was achieved using lentiviruses (Addgene
catalogue no. 21163). IMR-90 and MRC5 human diploid fibroblasts were pur-
chased from ATCC and 50,000 cells were used in reprogramming experiments.
SB431542 (Stemgent) was used at a final concentration of 2mM. TGF-b2 (R&D
Systems) was added daily at a concentration of 2 ngml21. Twist1 (Addgene
catalogue no. 1783), Snai1 (Addgene catalogue no. 23347) and Zeb1 (a gift of R.
A. Weinberg) were overexpressed using retro- or lentiviruses. Statistical analysis
was performed using a Student’s t-test.
Microarray analysis. Total RNA was extracted from two or three independent
culture plates for each condition with an RNeasy Mini kit (Qiagen). Synthesis of
complementary RNA from total RNA and hybridization/scanning of microarrays
were performed with Affymetrix GeneChip products (HGU133A) as described in
the GeneChip manual. Normalization of the raw gene expression data, quality
control checks and subsequent analyses were done with the open-source R-project
statistical software (http://www.r-project.org/) together with Bioconductor
packages. Raw data files (.CEL) were converted into probe set values by RMA
(robust multi-array averaging) normalization. Genes were selected at a threshold
of log ratio 0.4. The microarray data have been deposited in the National
Center for Biotechnology Information Gene Expression Omnibus (GEO) and
are accessible through GEO Series accession number GSE29253.
SYBR-Green real-time RT–PCR. Total RNA was extracted using an RNeasy
Mini kit coupled with an RNase-free DNase set (Qiagen) and reverse transcribed
withHexanucleotideMix (Roche). The resulting complementaryDNAswere used
for PCR using SYBR-Green Master PCR mix (Applied Biosystems) in triplicates.
All quantificationswere normalized to an endogenousb-actin control. The relative
quantification value for each target gene compared to the calibrator for that target
is expressed as 22(Ct2Cc) (Ct andCc are themean threshold cycle differences after
normalizing to b-actin). List of primers can be found in Supplementary Table 2.
Immunostaining. Immunostaining of reprogramming plates was performed as
described27. Briefly, cells were fixed with 4% paraformaldehyde and stained with
biotin-anti-Tra-1-60 (eBioscience, catalogueno. 13-8863-82, 1:250) and streptavidin
horseradish peroxidase (Biolegend, catalogue no. 405210, 1:500) diluted in PBS
(3%), FCS (0.3%) Triton X-100. Staining was developed with the Vector labs DAB
kit (catalogue no. SK-4100), and iPSC colonies quantified with ImageJ software.
For the characterization of shDot1l-iPS cells, we picked single colonies ontoMEF-
coated 96-well plates. The plates were fixed for 20min with 4% paraformaldehyde/
phosphate-buffered saline with calcium and magnesium (PBS (1/1)), washed
several times with PBS (1/1) and incubated overnight at 4 uC with primary
antibody and Hoechst stain diluted in 3% donkey serum/3% BSA Fraction VII/
0.01% Triton X-100/PBS (1/1); Hoechst, Invitrogen catalogue no. H3570
(1:20,000), Tra-1-81/A488 (BD catalogue no. 560174), SSEA-4/A647 (BD
catalogue no. 560219), Tra-1-60/A647 (BD catalogue no. 560122), Nanog, rabbit
polyclonal (Abcam catalogue no. ab21624), OCT4, rabbit polyclonal (Abcam
catalogue no. ab19857). For Nanog and OCT4, donkey anti-rabbit IgG/A555
(Molecular Probes catalogue no. A31572) secondary antibody was used. After
several washes with PBS (1/1), images were acquired using a BD Pathway 435
imager equipped with a 310 objective.
Teratoma formation assay. iPSCs grown on MEFs were harvested with
Collagenase IV (1mgml21 in DMEM/F12). Cell clumps from one six-well plate
were resuspended in 50ml DMEM/F12, 100ml collagen I (Invitrogen catalogue
no. A1064401) and 150ml hESC-qualifiedMatrigel (BDBiosciences#354277). Cell
clumps were then injected into the hind limb femoral muscles (100ml suspension
per leg) of Rag2 c/c mice. After 6–8weeks, teratomas were harvested and fixed in
Bouin’s solution overnight. Samples were then embedded in paraffin, and sections
were stained with haematoxylin/eosin (Rodent Histopathology Core, Harvard
Medical School).
Characterization of iPS cells. Embryoid body differentiation was performed as
described28.To check for the presence of the reprogramming transgenes, genomic
DNA was isolated using DNeasy Blood & Tissue Kit (Qiagen) and PCR was
performed with specific primers to the endogenous or the viral trangenes4.
ChIP-sequencing. ChIP-seq was performed as described with slight modifica-
tions12. 300,000 cells were fixed at room temperature in PBS 1% formalin (v/v) for
10min with gentle agitation. Fixation was stopped by the addition of glycine
(125mM final concentration) and agitation for 5min at room temperature.
Fixed cells were washed twice in ice-cold PBS, resuspended in 100ml of SDS lysis
buffer (1%SDS, 10mMEDTA, 50mMTris-HCl, pH8.1). Chromatin was sheared
by sonication to about 100–500 base pair fragments using a Bioruptor (diagenode)
and diluted tenfold with dilution buffer (0.01% SDS, 1.1% Triton-X100, 1.2mM
EDTA, 16.7mM Tris-HCl, pH8.1,167mM NaCl). Antibodies against specific
histone modifications were added to sonicated chromatin solution and incubated
at 4 uC overnight with gentle agitation. The antibodies used were anti-H3K27me3
(Millipore 07-449) and anti-H3K79me2 (abcam 3594). Immune complexes were
collected by incubation with 20ml of protein A/G agarose beads (Millipore) for an
hour at 4 uC with gentle agitation. Precipitates were washed sequentially with ice-
cold low-salt wash (0.1% SDS, 1% Triton-X-100, 2mM EDTA, 20mM Tris-HCl,
pH8.1, 150mMNaCl), high-saltwash (0.1%SDS, 1%Triton-X-100, 2mMEDTA,
20mM Tris-HCl, pH8.1, 500mM NaCl), LiCl wash (0.25M LiCl, 1% IGEPAL
CA-630, 1% deoxycholic acid, 1mM EDTA, 10mM Tris-HCl, pH8.1) and TE
wash (1mM EDTA, 10mM Tris-HCl, pH8.1) for 5min each at 4 uC with gentle
agitation. Samples were centrifuged briefly in between washes to collect the beads.
Immunoprecipitated DNA was eluted by incubating beads with 150ml elution
buffer (1%SDS, 0.1M NaHCO3) with gentle agitation for 15min at room tem-
perature. Elution was repeated once and eluates were combined, sodium chloride
(final concentration of 0.2M) was added to the eluate and eluates were incubated
at 65 uC overnight to reverse crosslinking. DNA was purified using PCR purifica-
tion spin columns (Qiagen). ForChIP sequencing, ChIPDNA libraries weremade
following Illumina ChIP-seq library preparation kit and subjected to Solexa
sequencing (Illumina) at the Center for Cancer Computational Biology, Dana
Faber Cancer Institute. Sequencing was performed on Illumina HiSeq2000. The
reads were aligned to the human genome hg18 using Bowtie29 and the reads that
mapped to multiple locations in the genome were discarded. We quantified the
histone modification level as the number of reads per million per kilobase in a
window of interest. The window was 1 kb upstream to 1 kb downstream from the
transcription start site (TSS) for H3K27me3 and 1 kb upstream to 2 kb down-
streamof theTSS forH3K79me2. To determine the significance of signal at a gene,
an empirical background model was estimated. Genes that showed interesting
pattern of histone methylation change were identified using iCanPlot (http://
www.icanplot.org). Geneset Overlap Analysis was performed by finding the over-
lap of a set of genes of interest with the gene sets in the collections c2.all, c3.all and
c5.all in MSigDB (total number of genesets in these collections is 5,562)30.
Hypergeometric test, with Bonferroni correction for multiple hypothesis testing,
was performed to generate the P values associated with gene set overlap analysis.
ChIP-Seq data have been deposited at the NCBI Gene Expression Omnibus with
accession number GSE35791.
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